New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the ...

Tim Anderson, BofA Securities senior pharma analyst, joins 'Squawk Box' to discuss news of Eli Lilly’s weight loss pill ...

Eli Lilly shares gained Tuesday as results from a new study moved the drugmaker closer to applying for approval of its ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

Eli Lilly has announced to go for global approval by the end of 2015 after completing the successful trials. The once-daily ...

While Truist Securities analysts said the results from the ATTAIN-2 trial leave “room for competition," they also pointed to ...

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral ...

Eli Lilly stated that results from a late-stage trial of its pill variant of GLP-1 drugs met the requirements for global ...

Eli Lilly & Co’s experimental obesity pill orforglipron helped patients lose 9.6% of their body weight in a late-stage trial, ...

Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of body weight in a late-stage trial, after recent data from another study of the drug in ...

Drugmaker Eli Lilly says its daily oral GLP-1 pill may help people who have obesity and people with Type 2 diabetes lose ...